Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia

Oropharyngeal Cancer Clinical Trial

Official title:

Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00330382
• Other study ID #: NCI-2009-00888
• Secondary ID: 98-34U01CA072294
• Status: Completed
• Phase: Phase 2
• First received: May 25, 2006
• Last updated: December 16, 2014
• Start date: January 1999
• Est. completion date: May 2013

Study information

• Verified date: February 2014
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This randomized phase II trial is studying how well Bowman-Birk inhibitor concentrate works in preventing cancer in patients with oral leukoplakia. Chemoprevention is the use of certain substances to keep cancer from forming, growing, or coming back. The use of Bowman-Birk inhibitor concentrate, a substance made from soy, may keep cancer from forming in patients with oral leukoplakia

Description:

PRIMARY OBJECTIVES:

I. Determine if chemoprevention by the Bowman-Birk inhibitor concentrate (BBIC) can prevent cancer in patients with oral leukoplakia (OL).

II. Determine the clinical and histologic response rate of OL to BBIC.

SECONDARY OBJECTIVES:

I. Measure the effect of BBIC on intermediate marker endpoint levels. II. Correlate the clinical and histologic responses of OL with cellular levels of proteolytic activity, erb-B2 (neu), retinioc acid receptor β, bcl-2, and mutant p53 expression, and serum levels of neu.

III. Determine the individual and group side effects of BBIC.

OUTLINE: This is a multicenter, randomized, double-blind, placebo-controlled, study. Prior to randomization, all patients receive oral placebo for 4 weeks. Patients who show good compliance (> 75% packet count) are randomized to 1 of 2 treatment arms.

ARM I: Patients receive oral Bowman-Birk inhibitor concentrate twice daily for 6 months in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive oral placebo twice daily for 6 months in the absence of disease progression or unacceptable toxicity.

Patients complete questionnaires about diet, tobacco, and alcohol usage at baseline and at the completion of study treatment. Blood, urine, and biopsy tissue are collected at baseline and at the completion of study treatment. Oral mucosal cells are collected at baseline, during the run-in phase, at randomization, after completion of study treatment, and at 3 months after completion of study treatment. Samples are examined for protease activity, levels of bcl-2 and erbB-2, mutant p53 oncogene expression and epidermal growth factor receptor, and retinoic acid receptor-β expression.

After completion of study treatment, patients are followed at 3 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 325
• Est. completion date: May 2013
• Est. primary completion date: July 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically and clinically confirmed oral leukoplakia and/or erythroplakia

• Bidimensionally measurable disease (= 100 mm^2 for total area of all lesions) after biopsy

• No presence of obvious head and neck aerodigestive tract cancer, carcinoma in situ, or previously treated head and neck cancer within the past 2 years

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No history of allergic reaction to soybeans, sorbitol, sucrose, artificial flavorings, aspartame, saccharin, or lidocaine

• At least 6 months since prior Bowman-Birk inhibitor concentrate

• At least 6 months since prior participation in another randomized clinical trail

• At least 3 months since prior systemic steroids or topical oral steroid preparations

• Topical nasal steroid sprays or cutaneous preparations with minimal systemic absorption for nasal or dermatologic disorders allowed

• More than 6 months since prior beta carotene capsules

• At least 2 years since prior retinoid or other beta carotene therapy, including > 25,000 IU of vitamin A for any reason

• Up to 2 multivitamins per day allowed

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Leukoplakia
• Leukoplakia, Oral
• Lip and Oral Cavity Cancer
• Lip Neoplasms
• Mouth Neoplasms
• Oral Leukoplakia
• Oropharyngeal Cancer
• Oropharyngeal Neoplasms
• Tongue Cancer

Intervention

Drug:
• Bowman-Birk inhibitor concentrate
Given orally

Other:
• placebo
Given orally
• laboratory biomarker analysis
Correlative studies

Locations

Country	Name	City	State
United States	University of California Medical Center At Irvine-Orange Campus	Orange	California

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (4)

Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ, Kerr AR, Meyskens FL Jr. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res (Phila). — View Citation

Armstrong WB, Wan XS, Kennedy AR, Taylor TH, Meyskens FL Jr. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment. Laryngoscope — View Citation

Meyskens FL Jr. Development of difluoromethyl-ornithine and Bowman-Birk inhibitor as chemopreventive agents by assessment of relevant biomarker modulation: some lessons learned. IARC Sci Publ. 2001;154:49-55. Review. — View Citation

Meyskens FL. Development of Bowman-Birk inhibitor for chemoprevention of oral head and neck cancer. Ann N Y Acad Sci. 2001 Dec;952:116-23. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relative Percent Change in Total Lesion Area After 6 Months on Study	Relative percent change in total lesion area was defined as 100 times (area posttreatment minus area pretreatment) all divided by pretreatment area.	6 months	No
Primary	Number of Participants by Category of Clinical Response at 6 Months	Category of clinical response was based on the magnitude of relative percent change in total lesion area. A complete response (CR) was declared if the relative percent change in total lesion area was minus 100 percent. A partial response (PR) was a relative percent decrease in total lesion area of 50% or more, without being a CR. Disease progression was a relative percent increase in total lesion area of at least 50%. Remaining cases were declared to be stable disease.	6 months	No
Secondary	The Difference in Rated Degree of Malignancy Between Randomization and 6-month Specimen	The reviewer was blinded to study-arm assignment (drug or placebo), but not to time point of specimen. For each specimen, the reviewer marked a continuum to indicate degree of tissue abnormality. The continuum was 140 mm long, and anchored by the word 'Normal' on the left and 'Malignant' on the right. The distance from the left edge of the continuum to the reviewer's mark, in mm, was determined. For analyses, a score was formed by subtracting the pretreatment value from the 6-month value. Thus, a retreat from 'Malignancy' over time produces a negative score, a score of zero denotes no change, and a positive score denotes a worsening situation. Positive values indicate histologic worsening, whereas negative scores denote improvement over the 6-month study period.	Baselie to 6 months	No
Secondary	Clinical Impression From Photographs	A secondary clinical response measure was bsaed on blinded, comparative judgments of pairs of photographs of the same lesion at baseline and 6 months on study. Picture pairs were assigned to album page, one pair per page, at random. Five physicians experienced with evaluation of oral mucosal tissue abnormalities, but blinded to study arm and time point, independently compared the pictures in each pair using a 7-point scale. The scale ranged from, "top photo shows a complete response relative to the bottom photo," through, "the same degree of disease is shown by top photo and bottom photo," to "bottom photo shows a complete response relative to the top photo." Raw scores were transformed to account for relative position of the earlier and later photo, and averaged across the 5 reviewers. Final scores ranged from one, denoting a CR at 6 months, to 4, which indicated no change, through 7, which indicated that the 6-month photo depicted a much worse situation than the pretreatment photo.	Baseline to 6 months	No
Secondary	Relative Percent Change in Buccal-Cell Neu Protein (ng/mg)	100% x (Posttreatment value - pretreatment value)/(pretreatment value)	Baseline to 6 months	No
Secondary	Relative Percent Change in Serum Neu Protein (ng/ml)	100% x (Posttreatment value - pretreatment value)/(pretreatment value)	Baseline to 6 months	No
Secondary	Relative Percent Change in Protease Activity (Delta RFU/Min/µg)	100% x (Posttreatment value - pretreatment value)/(pretreatment value)	Baseline to 6 months	No
Secondary	Number of Participants Report at Least 1 Adverse Event During the Study	The onset of adverse event is between the randomizaiton date and off-study date	Randomized date to Off-study date, up to 21 months	Yes
Secondary	Combined Percentage Change From Baseline in Proteolytic Activity, Buccal-cell Erb-B2 (Neu) and Serum Levels of Neu at 6 Months		Baseline to 6 months	No